Apogee Therapeutics released Phase II maintenance data for its IL‑13 antibody zumilokibart (zumi, APG‑777) showing durable skin and itch improvement with dosing every three or six months. Company disclosures reported high rates of sustained EASI‑75 responses at one year for both maintenance schedules, driving a strong market reaction and upgraded peak sales forecasts from analysts. The data were described in the Apex trial’s Part A; Apogee highlighted both depth and durability of response versus expectations. The results suggest a potential differentiated dosing convenience profile versus existing biologics such as dupilumab and Lilly’s Ebglyss, though confirmatory larger trials will be required. Investors and competitors will watch safety, larger efficacy cohorts, and head‑to‑head or real‑world differentiators; if replicated in registrational studies, less‑frequent dosing could alter treatment economics and patient adherence.